At BioCanim, we are pioneering a next-generation cancer immunotherapy designed to revolutionize the treatment of solid tumors. Our innovative approach focuses on intratumoral immunotherapy, directly targeting the tumor microenvironment to enhance immune recognition and activation, overcoming the barriers that often limit the effectiveness of systemic treatments.
By leveraging advanced immunomodulatory strategies, we aim to stimulate both the innate and adaptive immune systems, turning the tumor itself into a focal point for immune attack. Our goal is to create therapies that not only shrink tumors but also generate long-lasting immune responses capable of preventing cancer recurrence.
Company Details
- Founded
- -
- Address
- Prague , Cz
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Faculty of Medicine.
- HQ
- Prague
Biocanim A.s. Questions
Biocanim A.S.'s LinkedIn profile is https://cz.linkedin.com/company/biocanim-a-s
Biocanim A.S.'s industry is
Biotechnology Research
Biocanim A.S.'s top competitors are
American Association For Cancer Research,
Bioinova, A.s.,
3genes,
Easy Immuno-Atmps,
Institute Of Biotechnology Of The Czech Academy Of Sciences,
Faculty Of Medicine, Masaryk University,
Phenomenex.
Biocanim A.S.'s categories are Biotechnology Research
Biocanim A.S.'s founding year is 2023
